



17414 U.S. PTO
09/30/03

UTILITY PATENT APPLICATION TRANSMITTAL		Attorney Docket No.: 05015.0366U4			
(Only for new nonprovisional applications under 37 CFR 1.53(b))		First Inventor: Buchanan <i>et al.</i>			
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility application contents		Title: ACYLATED CYCLODEXTRIN: GUEST MOLECULE INCLUSION COMPLEXES			
		Express Mail Label No.: EL992019711US			
		ADDRESS TO: Mail Stop PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450			
1. <input checked="" type="checkbox"/> Specification [Total Pages 49] (Includes description, claims, and abstract)		6. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large tables or Computer Program (Appendix)			
2. <input checked="" type="checkbox"/> Drawings [Total Sheets 15]		ACCOMPANYING APPLICATION PARTS: 7. <input type="checkbox"/> Copy of Assignment 8. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee) 9. <input type="checkbox"/> Power of Attorney 10. <input type="checkbox"/> English Translation Document (if applicable) 11. <input checked="" type="checkbox"/> Information Disclosure Statement/PTO-1449 <input type="checkbox"/> Copies of IDS Citations [Total Citations ____] 12. <input type="checkbox"/> Preliminary Amendment 13. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed) 14. <input type="checkbox"/> Nonpublication Request under 35 USC 122(b)(2)(B)(i) (Must attach form PTO/SB/35 or equivalent). 15. <input checked="" type="checkbox"/> Authorization to Treat Reply Requiring Extension of Time as Incorporating Petition for Extension of Time 16. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) 17. <input checked="" type="checkbox"/> Other: Communication			
3. <input checked="" type="checkbox"/> Oath or Declaration [Total Pages 4] a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 20B completed)					
4. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 [Total Pages ____]					
5. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input type="checkbox"/> Computer Readable Form (CRF) --OR-- <input type="checkbox"/> Statement under 37 CFR 1.821(e) (see Box 21 for statement) b. <input type="checkbox"/> Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> paper [Total Pages ____] c. <input type="checkbox"/> The contents of the computer readable form of the sequence listing and the sequence listing in the specification of the application are the same.					
18. The FILING FEE is calculated as follows: (Claims as filed, less any claims cancelled by Amendment)					
Claims		Number Filed	Number Extra	Rate	Basic Fee \$750.00
Total claims		59 - 20 =	39	X \$18.00	\$702.00
Independent claims		3 - 3 =	0	X \$84.00	\$0.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ 280.00	\$0.00
TOTAL OF ABOVE CALCULATIONS =					\$1,452.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. Fees are reduced by 1/2. -					\$0.00
TOTAL FILING FEE =					\$1,452.00
19. Payment:					
<input type="checkbox"/> A check in the amount of \$_____ is enclosed.					
<input checked="" type="checkbox"/> Credit Card Payment Form PTO-2038 Authorizing Payment in the amount of \$1,452.00 is enclosed.					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional amount due or credit any overpayment to Deposit Account No. 14-0629.					

031088 U.S. PTO
10/675900

093003

20A.	<input type="checkbox"/>	This application is an original application (<u>not</u> a continuation, divisional or continuation-in-part).
20B.	<input checked="" type="checkbox"/>	<p>This application is a <input type="checkbox"/> continuation-in-part / <input type="checkbox"/> continuation / <input checked="" type="checkbox"/> divisional of prior Application No. <u>09/843,037</u>.</p> <p>The prior application was assigned to Examiner <u>Leigh C. Maier</u>, Group Art Unit <u>1623</u>.</p> <p>The entire disclosure of the prior application is considered a part of the disclosure of the accompanying application and is hereby incorporated by reference.</p> <p><input checked="" type="checkbox"/> This application is a continuation or divisional application (<u>not</u> a continuation-in-part) that:</p> <ul style="list-style-type: none">(i) names as inventors the same or fewer than all the inventors named in the prior application; and(ii) contains no matter that would have been new matter in the prior application; and(iii) a copy of the executed oath or declaration in the prior application, showing the signature or an indication thereon that it was signed: <div style="margin-left: 40px;"><input checked="" type="checkbox"/> is enclosed. <input type="checkbox"/> will follow.</div> <p><input type="checkbox"/> This application is a continuation or divisional application (<u>not</u> a continuation-in-part) that is being filed by less than all the inventors named in the prior application. In accordance with 37 C.F.R. §1.63(d)(2), the Commissioner is requested to delete the name(s) of the following person who are not inventors of the invention being claimed in this application:</p> <p><input type="checkbox"/> This application is a continuation-in-part, continuation or divisional application naming an inventor not named in the prior application. A newly executed oath or declaration: <div style="margin-left: 40px;"><input type="checkbox"/> is enclosed. <input type="checkbox"/> will follow.</div></p>
21.	<input type="checkbox"/>	<p>A sequence listing in computer readable form in compliance with 37 C.F.R. §§ 1.821-1.825 was submitted on _____ in prior Application No. _____, filed _____.</p> <p>Pursuant to 37 C.F.R. § 1.821(e), applicant hereby requests that the computer readable form of the sequence listing submitted in the above-referenced prior application be used as the computer readable form of the sequence listing for the new application. The paper or compact disk copy of the Sequence Listing in the new application is identical to the computer readable copy filed in the prior application.</p>
22.	<input type="checkbox"/>	<p>This application claims foreign priority benefits under 35 USC 119(a)-(d) or 365(b) of any foreign application(s) listed below, or under 35 USC 365(a) or 365(b) of any PCT application listed below.</p> <p>Application No. _____ Country: _____ Day/Month/Year Filed: _____</p>
23. Address all correspondence to the address associated with: CUSTOMER NO. 23859		
Name of Attorney/Agent: Jacqueline M. Hutter		Registration No.: 44,792
Signature: 		Date: 9/30/03
Certificate of Express Mailing Under 37 C.F.R. § 1.10		
I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as Express Mail, Label No. EL992019711US, in an envelope addressed to: Mail Stop PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.		
 Michael Laird		<u>9/30/03</u> Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	BUCHANAN <i>ET AL.</i>)		
)		
App. Serial No.:	Rule 1.53(d) Divisional of)	Confirmation No.	Unassigned
	Application No. 09/843,037)		
	Filed April 26, 2001)	Group Art Unit:	Unassigned
)		
Filed:	Concurrently)	Examiner:	Unassigned
)		
Title:	ACYLATED CYCLODEXTRIN:)		
	GUEST MOLECULE)		
	INCLUSION COMPLEXES)		

AUTHORIZATION TO TREAT REPLY REQUIRING
EXTENSION OF TIME AS INCORPORATING PETITION
FOR EXTENSION OF TIME

MAIL STOP PATENT APPLICATION
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859


September 30, 2003

Sir:

Pursuant to 37 C.F.R. § 1.136(a)(3), the Commissioner is hereby requested and authorized to treat any concurrent or future reply in the above-identified application, requiring a petition for an extension of time for its timely submission, as incorporating a petition for extension of time for the appropriate length of time.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.



Jacqueline M. Hutter
Registration No. 44,792

ATTORNEY DOCKET NO.: 05015.0366U4
APPLICATION NO.: Rule 1.53(d) Divisional of
Application No. 09/843,037
Filed April 26, 2001

NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300 Phone
(678) 420-9301 Fax

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as Express Mail, Label No. EL992019711US, in an envelope addressed to: MAIL STOP PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.



Michael Laird

9/30/03

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	BUCHANAN <i>ET AL.</i>)		
)		
App. Serial No.:	Rule 1.53(d) Divisional of)	Confirmation No.	Unassigned
	Application No. 09/843,037)		
	Filed April 26, 2001)	Group Art Unit:	Unassigned
)		
Filed:	Concurrently)	Examiner:	Unassigned
)		
Title:	ACYLATED CYCLODEXTRIN:)		
	GUEST MOLECULE)		
	INCLUSION COMPLEXES)		

COMMUNICATION

MAIL STOP PATENT APPLICATION
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer Number 23859

September 30, 2003

Sir:

This Communication accompanies a Rule 1.53(b) Divisional Application of Application No. 09/843,037, filed April 26, 2001.

In Application 09/843,037, Examiner Leigh Maier issued a Restriction Requirement on April 2, 2003, restricting the claims into four groups, Groups I through IV. However, in this Restriction Requirement the disposition of claims 49-65 was not identified. In a telephone call on September 8, 2003, the undersigned discussed the apparent mistake with Examiner Maier and Examiner Maier acknowledged the inadvertent omission of claims 49-65 from the Restriction Requirement and stated that these claims were part of Group III. Accordingly, the Divisional Application submitted herewith contains what Applicants believe are all the claims grouped into


ATTORNEY DOCKET NO.: 05015.0366U4
APPLICATION NO.: Rule 1.53(d) Divisional of
Application No. 09/843,037
Filed April 26, 2001

Group III by Examiner Maier in the Restriction Requirement issued for the parent application, namely, claims 24-82.

CONCLUSION

Included herewith is payment in the amount of \$1,452.00 for the Application filing fee. This payment is to be charged to a credit card and such payment is authorized by the signed, enclosed document entitled: Credit Card Payment Form PTO-2038. No additional fee is believed to be due; however, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment in fees to Deposit Account No. 14-0629.


Respectfully submitted,
NEEDLE & ROSENBERG, P.C.


Jacqueline M. Hutter
Registration No. 44,792

NEEDLE & ROSENBERG, P.C.
Customer No. 23859
(678) 420-9300 Phone
(678) 420-9301 Fax

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as Express Mail, Label No. EL992019711US, in an envelope addressed to: MAIL STOP PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.


Michael Laird


Date